*Optimal dilutions/concentrations should be determined by the researcher.
Not tested in other applications.
A431 , H1299 , HeLa , HepG2
IP/MS validation was supported by references (PMID:30377376)
0.1M Tris, 0.1M Glycine, 10% Glycerol (pH7). 0.01% Thimerosal was added as a preservative.
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
0.8 mg/ml (Please refer to the vial label for the specific concentration.)
Recombinant protein encompassing a sequence within the center region of human Bid. The exact sequence is proprietary.
Purified by antigen-affinity chromatography.
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
BH3 interacting domain death agonist,FP497
Cytoplasm , Mitochondrion membrane , BH3-interacting domain death agonist p15: Mitochondrion membrane , BH3-interacting domain death agonist p13: Mitochondrion membrane , Isoform 1: Cytoplasm , Isoform 3: Cytoplasm , Isoform 2: Mitochondrion membrane
This gene encodes a death agonist that heterodimerizes with either agonist BAX or antagonist BCL2. The encoded protein is a member of the BCL-2 family of cell death regulators. It is a mediator of mitochondrial damage induced by caspase-8 (CASP8); CASP8 cleaves this encoded protein, and the COOH-terminal part translocates to mitochondria where it triggers cytochrome c release. Multiple alternatively spliced transcript variants have been found, but the full-length nature of some variants has not been defined. [provided by RefSeq]